Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 15;9(1):19.
doi: 10.1186/1742-6405-9-19.

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort

Arlene C Chua  1 , Ryan M Llorin, Kelvin Lai, Philippe Cavailler, Hwa Lin Law
Affiliations

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort

Arlene C Chua et al. AIDS Res Ther. .

Abstract

Background: Tenofovirdisoproxilfumarate (TDF) is a nucleotide analogue widely recommended in international HIV treatment guidelines. The association of TDF and renal dysfunction has remained an area of interest.

Findings: We conducted a retrospective review of all patients on TDF from July 2007 to December 2009 in our institution and evaluated their renal function. Absolute change of creatinine clearance (CLCr) using Cockroft-Gault equation from baseline was calculated at 6, 12, 18 and 24 months. Overall, 226 patients were included in the study. Ninety percent were male. The median age was 46 yrs old (23-82), median weight was 60 kg (IQR 53.75-68), median CD4 count was 127 cells/mm3 (IQR 38-258) and median CLCr 82.7 mL/min (IQR 71.4-101.7) on initiation of TDF. The median decline of CLCr from baseline was -3.9 ml/min (IQR -12.3 to 7.6), and -3.6 ml/min (IQR -12.4 to 6.7) at 12 (n = 102), 24 months (n = 75) respectively. Eighteen of 226 patients had a decline in renal function to </=50 ml/min. Majority of which had an improvement of CLCr on follow up. Only 80% of patients ever received monitoring of renal function.

Conclusion: While we noted renal toxicity to be rare and transient among our cohort receiving TDF as part of their ARV regimen, these results reflect the short term renal effects of TDF given that ARV treatment is lifelong. Given that laboratory monitoring may be difficult to implement in many situations, future prospective studies looking into an evidence based algorithm for less frequent renal function monitoring than current guideline recommendations may be helpful.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Median Creatinine Clearance over time.
See this image and copyright information in PMC

References

    1. Bucher HC, Wolbers M, Porter K. Guidelines for antiretroviral treatment of HIV from the International AIDS Society-USA Panel. JAMA. 2010;304(17):1897–1898. - PubMed
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Editor; 2011.
    1. World Health Organization. HIV/AIDS Department, Antiretroviral Therapy For HIV Infection in Adults and Adolescents, Recommendations for a Public Health Approach. WHO, Editor; 2010. - PubMed
    1. Arribas JR. et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47(1):74–78. doi: 10.1097/QAI.0b013e31815acab8. - DOI - PubMed
    1. Gallant JE. et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201. doi: 10.1001/jama.292.2.191. - DOI - PubMed